Alps Advisors Inc Viridian Therapeutics, Inc.\De Transaction History
Alps Advisors Inc
- $14.8 Billion
- Q3 2024
A detailed history of Alps Advisors Inc transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Alps Advisors Inc holds 46,825 shares of VRDN stock, worth $867,667. This represents 0.01% of its overall portfolio holdings.
Number of Shares
46,825
Previous 49,766
5.91%
Holding current value
$867,667
Previous $647,000
64.61%
% of portfolio
0.01%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding VRDN
# of Institutions
180Shares Held
76.7MCall Options Held
581KPut Options Held
439K-
Black Rock Inc. New York, NY4.77MShares$88.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.42MShares$81.9 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$71.9 Million9.15% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.75MShares$69.5 Million3.15% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.45MShares$63.9 Million12.74% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $739M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...